Basel Innovation Park Main Campus Expands Flexible Infrastructure for Biopharma Startups and Manufacturing

Flexible laboratory and manufacturing infrastructure is playing an increasingly important role in supporting biotechnology startups, academic researchers, and emerging biopharmaceutical companies, says Johannes Eisenhut, PhD, CEO of SENN Development, a Swiss real estate development company focused on laboratory and innovation space development.

Speaking to BioPharm International® about the Switzerland Innovation Park Main Campus, Dr. Eisenhut highlights investments designed to bridge early-stage development and commercial manufacturing. He notes that a major laboratory and pharmaceutical production infrastructure provider has invested millions of dollars in a preproduction facility in which companies can evaluate manufacturing systems, test processes, and generate material for clinical studies before scaling to larger commercial production lines.

“One important aspect of Switzerland Innovation Park Main Campus is that we have academia and commercial businesses working together,” Dr. Eisenhut says.

The campus also houses the Department of Biomedical Engineering of the University of Basel, which Dr. Eisenhut describes as a source of advanced biomedical research. He cites examples such as three-dimensional printed bone technologies and magnesium-based structures designed to replace missing bone tissue.

How does shared infrastructure support biopharma startup development?

According to Dr. Eisenhut, a key component of the campus is the presence of the Switzerland Innovation Park Basel Area, which provides pre-equipped laboratory and office space for startup companies. The organization uses government-backed funding mechanisms to help absorb risks associated with early-stage ventures, allowing startups to access research infrastructure without committing to long-term facility investments.

Dr. Eisenhut explains that campus buildings are designed with flexibility in mind to accommodate a range of research and manufacturing activities. In addition to supporting employee collaboration and workplace well-being, the facilities are configured to adapt to changing tenant needs.

He points to a recently completed facility that can accommodate both large and small tenants while supporting applications ranging from research laboratories to good manufacturing practice (GMP) production environments. This flexibility, he states, enables companies to expand operations without relocating as their development programs mature.

Watch Dr. Eisenhut’s interview about Basel’s growing life sciences ecosystem here.

About the speaker

Johannes Eisenhut, PhD, CEO, SENN Development

Dr. Eisenhut leads strategic development and innovation initiatives as a member of the group management board of SENN. With a career spanning international marketing, brand development, and real estate, he previously served as head of Marketing Europe for Burton Snowboards and co-founded /Department United Creative Forces (now FCB Zürich). A former professional snowboarder, he holds a PhD in cognitive linguistics from the University of Fribourg and has co-founded several Swiss innovation initiatives, including X27 and Made in Zurich.